Comparison of Lao generic drugs and original drugs of Brigatinib (Brigatinib)

Brigatinib (Brigatinib), as a targeted therapy for ALK (anaplastic lymphoma kinase) gene mutation-positive non-small cell lung cancer (NSCLC), has attracted much attention for its efficacy. As a type of tyrosine kinase inhibitor (TKI), brigatinib (brigatinib) effectively suppresses the growth of tumor cells by precisely inhibiting the activity of ALK kinase. Long and spreading, it is especially suitable for patients who are resistant to first-line ALK inhibitors such as crizotinib, and has demonstrated significant therapeutic effects on specific ALK mutation types.

Brigatinib has a unique mechanism of action. It can interfere with the signaling pathways of cancer cells by preventing the phosphorylation of ALK kinase. The drug can specifically bind to the ATP binding site of ALK kinase, thereby blocking its activity and inhibiting the proliferation of tumor cells. At the same time, Brigatinib also exhibits a certain inhibitory effect on ROS1 kinase, indicating its potential application value in the treatment of ROS1 mutated tumors.

In the Chinese market, the price of the original drug of brigatinib is roughly RMB 4,000 to 5,000 yuan per box. Thanks to the coverage of medical insurance policies, patients can enjoy partial expense reimbursement, which relieves patients' financial pressure to a certain extent.

However, for patient groups with limited financial resources, generic drugs have become a more affordable option. In countries such as Laos, the price of generic drugs of brigatinib has been significantly reduced, with each box only costing a few hundred yuan. Despite their low prices, these generic drugs are highly consistent with the original drugs in terms of their main ingredients and therapeutic effects. It is worth noting that when patients choose to purchase generic drugs, they must go through formal channels to ensure the quality and therapeutic effect of the drugs.

In summary,Brigatinib (Brigatinib) , as a targeted therapy with significant efficacy, is ALKNew treatment hope for patients with mutation-positive non-small cell lung cancer. The emergence of generic drugs has further improved the accessibility of the drug, allowing more patients with limited economic conditions to obtain effective treatment.